Value Of BioZ.com Noninvasive Hemodynamic Monitoring System In Real-time Adjusting Ultrafiltration Rate In Patients Undergonging Maintenance Hemodialysis

Objective : To investigate the clinical significance of BioZ.com noninvasive hemodynamic monitoring system guiding the setting of ultrafiltration volume of hemodialysis for maintaining stable hemodynamics in patients with end-stage renal disease.Methods:We enrolled 41 patients with end-stage renal disease who were administrated with maintenance hemodialysis treatment in the Center of Blood Purification, the Fourth Hospital of Hebei Medical University from February to July in 2014.Using random number table method, the patients were divided into two groups, the control group(n=21) and trail group(n=20). Hemodynanmics was monitored according to the operating instrctions of BioZ.com noninvasive hemodynamic monitoring system.In trail group, real-time adjustment was made on ultrafiltrstion volume according to thoracic fluid content(TFC), in control group, conventional adjustment was made on ultrafiltration volume. TFC and hemodynamic parameters before and after hemodialysis were recorded, and relevant adverse events were recorded during hemodialysis, including palpitation,hypotention and muscle spasm.Results:1 Before hemodialysis, the control group were not significantly different in hemodynamic parameters(P>0.05).2 The CO, CI, SV, SI, LVET, LCW, LCWI of posthemodialysis was lower and SVR, SVRI, PEP, STR, MAP was higher than prehemodialysis in the control group. The CO, CI, SV, SI, LVET of posthemodialysis was lower and SVR, SVRI, PEP, STR was higher than prehemodialysis in the trial group.3 When hemodialysis ended, trial group was higher in CO, SV, LCW, LCWI and lower in MAP than control group(P<0.05). The TFC of control group before hemodialysis was40.2(11.3) /? and was 32.7(8.7) /? after hemodialysis, and the TFC of trail group was 40.4(8.4) /? before hemodialysis and 32.4(4.3) /? after hemodialysis; the two groups had no sifnificant changes in △TFC after hemodialysis(t=1.611, P>0.05).4 Adverse events relevant with hemodynamics occurred in 5(23.8%)patients in control group, among which 1 patient had palpitation and 4 patients had hypotention; no adverse events relevant with hemodialysis occurred in trial group. Trial group was lower than control group in the incidence of adverse events(P=0.048).Conclusion:The application of BioZ.com noninvasive hemodynaminc monitoring system in the guidance of the setting and real-time adjusting of ultrafiltration volume of hemodialysis could maintain the stability of hemodynamics, improve the cardiac function and reduce the adverse events relevant with hemodialysis.